ASH 2014: Mixed results for PD-1, CAR-T in blood cancers

The 56th American Society of Hematology (ASH) Annual Meeting and Exposition from 6 to 9 December in San Francisco will give immunotherapy developers a chance to present efficacy (or lack thereof) in hematological malignancies after a fairly strong showing at this summer's American Society of Clinical Oncology (ASCO) conference (scripintelligence.com, 5 June 2014).